A Phase I/II Study of Hyperimmune IVIG in Slowing Progression of Disease in HIV-Infected Children
Status:
Completed
Trial end date:
1998-04-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety, tolerance, pharmacokinetics, and antiviral activity of human anti-HIV
immune serum globulin ( HIVIG ) at three dosage levels in HIV-infected children.
Passive antibody therapy has been used with limited success in treating advanced HIV disease
in adults. HIVIG is manufactured from HIV antibody-rich plasma taken from asymptomatic
donors. It is hypothesized that HIVIG will decrease the viral burden of moderately advanced
HIV-positive children.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)